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Intracerebral hemorrhage (ICH) accounts for 2 million (10-15%) of all 15 million strokes 
worldwide each year. Over the last decades, many research trials have sought to understand ICH, 
improve patients’ functional outcomes, and lower mortality. This thesis presents power analyses 
based on simulating data from the Minimally Invasive Surgery (MIS) with thrombolysis in a 
Phase 2 (MISTIE II) and a Phase 3 (MISTIE III) trial. We introduce different scenarios in these 
simulations. The trial designs consist of four main parts: (1) binary endpoint versus ordinal 
endpoint, (2) futility stopping rules, (3) MIS evacuation timing, and (4) patients’ clot size at the 
end of surgery. This work aims to provide the appropriate rationale for MIS training in future 
studies. From the results, we suggest future clinical studies should have as many patients as 
possible achieving 15cc or less clot size at the end of MIS. It is reasonable if the sample size of 
each arm ≥ 800 with power = 80%. If clinicians prefer a smaller sample size, then analysis of 
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Intracerebral hemorrhage (ICH) is a disastrous event caused by ruptured vessels affected by 
hypertension-related degenerative changes or cerebral amyloid angiopathy.[1] ICH accounts for 
2 million (10-15%) of all 15 million strokes worldwide each year.[2] It has a very high morbidity 
and mortality rate that has not changed over the last 30 years. [3] Unfortunately, there is still no 
evidence-based primary treatment for this condition.[4][5]  
Over the last decades, many research trials have sought to understand ICH, improve functional 
outcomes, and lower mortality. Since the modified Rankin Scale (mRS), a 7-level ordered 
categorical score ranging from 0 (no symptoms at all) to 6 (dead), has been regarded as a valid 
and reliable endpoint in randomized clinical trials, it is recommended to represent outcomes for 
stroke studies in estimating the degree of disability for patients who have had a stroke. [6][7][8] 
The Minimally Invasive Surgery (MIS) with thrombolysis in a Phase 2 trial (MISTIE II) and 
Phase 3 (MISTIE III) trial both used the mRS to measure patients’ functional outcome. MISTIE 
II shows the advantage of patients’ functional outcomes at interim analysis 180 days.[9] 
Exploratory analysis in MISTIE III mentions an association between the extent of clot removal 
and lower mRS scores. It points out the need for an additional clinical trial in estimating the 
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effect of this therapy. [10][11] In particular, more investigation needs to be performed on the 
timing and optimal performance of MIS. Therefore, a power analysis based on MISTIE II/III and 
more rigorous MIS performance criteria are important in providing an appropriate rationale for 
training and clinical experience in the future. 
1.2 Statistical background 
When researchers plan a study, the required sample size is always a big concern. To provide an 
appropriate sample size, evaluating the statistical power based on simulation is one strategy. In 
this simulated study, power is the probability of finding a statistical difference between MISTIE 
and standard medical treatment performance in patients’ functional outcomes when the average 
treatment effect is the minimum, clinically meaningful treatment effect.  
We also consider the impact of a futility analysis. Early futility stops can minimize patients’ 
exposure to ineffective treatments and save the use of resources. Conditional power is a popular 
strategy to examine the futility of a trial. In addition, there exist meta-analysis studies suggesting 
that beneficial effects remain true when analyzing evacuation timing subgroups. [12] Therefore, 
in this simulated study, we would like to examine the statistical difference in treatment effect 
considering the futility.   
Our main contribution is to simulate a randomized clinical ICH trial using data derived from 
MISTIE II/III. We estimate statistical power under the case of a binary endpoint versus ordinal 
endpoint for various sample sizes, consider the probability of removing one or both of two 
different surgery intervention arms due to futility, and evaluate and quantify various trial results 
at the completion of simulated patient recruitment. 
1.3 Organization of This Article   
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Chapter 2 introduces the demographics and clinical characteristics with results in binary endpoint 
versus ordinal endpoint based on MISTIE II/III patients. Chapter 3 compares the statistical 
power under two endpoint scenarios (binary and ordinal outcomes). Chapter 4 further evaluates 
the statistical power using simulated data while considering futility and multiple comparisons. 





























Chapter 2  
 
Basic information  
 
The data are derived from two sources: MISTIE II (clinicaltrials.gov NCT00224770), a 
multicenter, randomized, and open-label phase 2 trial; MISTIE III (clinicaltrials.gov 
NCT01827046), a multicenter randomized, controlled, open-label, blinded endpoint phase 3 trial. 
All patients are over the age of 18 and have a Historical Rankin score of 0 or 1. Participants have 
a Glasgow Coma Scale (GCS) 14 or less or a National Institute of Health Stroke Scale 6 or more 
at the time of presentation.[9][10] Patient functional outcome is estimated by modified Rankin 
Scale(mRS) score. 
2.1 Basic Demographic and Clinical Characteristics  
Demographic and baseline characteristics for the whole dataset can be found in table 2.1. 
“Stability CT ICH” denotes Stability CT Intracerebral hemorrhage(ICH) volume, “Stability CT 
IVH” denotes Stability CT Intraventricular hemorrhage (IVH) volume, Glasgow Coma Scale 
(GCS) is a scoring system used to describe patients’ degree of consciousness following a brain 




Table2.1 Demographic and baseline characteristics for MISTIE II/III, “mRS”: Patients Modified Rankin 
Scale(mRS) - ordinal at day 180, range from 0 to 6 where 0 is no symptom, 1 is no significant disability and 
able to carry out all pre-stroke activities, 2 is slight disability and unable to carry out all pre-stroke activities, 
3 is moderate disability with requiring some external help, 4 is moderately severe disability and unable to 
walk or attend to bodily functions without others’ assistance, 5 is severe disability with requiring continuous 





2.2 Model Results  
2.2.1. MISTIE vs. Medical 
We perform statistical analysis with the completed data (581 patients) using the 
generalized logistic regression model and generalized ordinal logistic regression model. 
For the generalized logistic regression model, the outcome is defined as the proportion of 
patients who achieved an mRS score of 0-3 at 180 days; for the generalized ordinal 
logistic regression model, the ordinal outcome is defined as the proportion of patients 
who achieved an mRS score of 0-2, 3, 4, 5, 6 at 180 days. Differences between MIS and 
medical group with adjustment in baseline covariates (stability intracerebral hemorrhage 
size, stability intraventricular hemorrhage size, age, GCS, clot location) are examined 
under these two scenarios. The result is shown in Table 2.2.1.1. 
 
                                                         
Table 2.2.1.1 Comparsion of the binary endpoint versus ordinary endpoint model results with covariate 




2.2.2 MIS vs. Medical regarding patients symptom onset to surgery hours 
Regarding the time duration from patients’ symptoms onset to surgery time, most patients 
received surgery between 40 to 75 hours after symptom onset (Figure 2.2.2.1). Patients 
were separated into two groups, early surgery and late surgery groups, by median (55 
hours) of symptoms onset to surgery. Demographic and baseline characteristics are 
shown in Appendix 1. 
Statistical analysis is performed by using the generalized logistic regression model and 
generalized ordinal logistic regression model. The outcome is defined as the same in 2.2a 
for both models. Treatment differences between each of the three groups (late, early, 
medical) with adjustment for baseline covariates (stability intracerebral hemorrhage size, 
stability intraventricular hemorrhage size, age, GCS, clot location) are examined. The 
result is shown in table 2.2.2.1 and table 2.2.2.2. 
 
 
Figure 2.2.2.1 Distribution of ICH patients’ symptom onset to MIS surgery time. The red dashed line 






Table 2.2.2.1 Binary endpoint model results. Left: Early Surgery patients (n=136) versus standard medical 




Table 2.2.2.2 Ordinal endpoint model results. Left: Early Surgery patients (n=136) versus Standard 
medical patients; Right: Late Surgery patients(n=139) versus standard medical patients; nominal specifies 





Chapter 3  
 




This chapter aims to estimate and compare statistical power under two scenarios: (1) Binary 
endpoint via generalized logistic regression model; and (2) Ordinal endpoint via generalized 
ordinal logistic regression model. We also explore the impact of higher percentage participants 
achieving clot size 15cc or less at the end of treatment in computing statistical power. Both 
scenarios are performed without covariate adjustment. In each scenario, we simulate MIS and 
medical groups with 1:1 randomization to the two arms with total enrollments of n = 350, 500, 
600, 800, and 1000. We generate data for standard medical-arm participants by resampling with 
replacement from the original control group of MISTIE data. The “no enriched” MIS arm 
participants are generated by resampling with replacement from the initial surgery group of 
MISTIE data. Data for “enriched” MIS-arm participants are simulated in two steps: (1) Dividing 
original MISTIE data by patients clot size ≤ 15 and > 15 cc at the end of treatment. (2) 
Participants who reach clot sizes less than 15 and greater than 15 cc are resampled with 
replacement from each stratum to reach prespecified ratios = 9:1, 8.5:1.5, 8:2, 7:3. We compare 
the power of binary endpoint to the ordinal endpoint with different percentages of patients 
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having 15cc or less clot at the end of treatment in each simulated MISTIE arm. These endpoints 
are defined as below and implemented in the R studio.  
3.2 Binary and Ordinal Endpoint 
In binary endpoint, Odds Ratio is the ratio of odds of good functional outcome (mRS 0-3) 
comparing the MIS surgery group to the standard medical group.  
Odds(Y = 1| A = 1)/Odds (Y=1|A = 0) Y: functional outcome, A: group{1: surgery, 0: medical} 
For ordinal endpoint,  its outcome has 5 levels: mRS0-2(level1), mRS 3(level 2), mRS 4(level 3), 
mRS 5(level 4), mRS 6(level 5). 
Cumulative log Odds Ratio: cumulative log odds ratio of functional outcome at level 1 to level k 
comparing the MIS surgery group to the standard medical group. 
3.3 Performance criteria 
We compare the type I error with significance level 0.05 and power of test regarding the null 
hypothesis 𝐻0: no effect of MIS treatment compared to standard of care (medical treatment) 




















350 Binary 0.097 0.345 0.543 0.663 0.768 
500 Binary 0.132 0.439 0.722 0.815 0.902 
600 Binary 0.155 0.512 0.787 0.872 0.939 
800 Binary 0.210 0.643 0.888 0.952 0.971 
1000 Binary 0.250 0.765 0.955 0.979 0.995 
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350 Ordinal 0.371 0.732 0.884 0.946 0.961 
500 Ordinal 0.497 0.859 0.972 0.990 0.997 
600 Ordinal 0.581 0.916 0.987 0.997 1 
800 Ordinal 0.701 0.966 1 1 1 
1000 Ordinal 0.796 0.994 0.999 1 1 
Table3.4.1 Simulated power results for the binary outcome and ordinal outcome under the different scenarios. N 
denotes simulated arm size for the MIS and the standard medical groups; “Enhancement” denotes the proportion of 
patients having 15cc or less clot at the end of treatment in simulated MIS arm.  
 
3.5 Discussion 
In Table 3.4.1, the first five rows compare the performance of the binary outcomes in different 
treatment arm sizes where the good functional outcome is defined as patients achieve mRS 0-3 at 
180 days. After considering different enhancement proportions, absolute gains in power vary 
from 15% to 42% when arm size increases from 350 to 1000. As seen in Table 3.4.1, the last five 
rows compare the ordinal outcomes in the different arms. The covariates-adjusted method 
achieves higher power when arm size becomes larger. After considering different enrichment 
proportions, absolute gains in power vary from 4% to 42% when arm size increases from 350 to 
1000. Overall, Table 3.4.1 shows that performing ordinal endpoint and higher percentage 
enhancement in patients with 15cc or less clot size at the end of treatment can achieve higher 
power than binary endpoint across all settings. Absolute gains in power vary from 4% to 42%. 
Under some scenarios, power reaches 100%, and we conclude it is a possible overpower issue 
and should consider whether we waste clinical resources in enrolling unnecessary patients. 








Interim analysis in MIS Arm versus standard medical arm 
with the binary outcome  
 
4.1 Introduction 
This chapter aims to compare various trial results when considering different percentage 
participants achieving clot size 15cc or less, evacuation timing, and the probability of dropping 
MIS intervention arms due to futility. The resulting multiple comparison problem is also taken 
into account. Late phase trials often recruit hundreds or thousands of participants. It is reasonable 
to consider whether the trial should be stopped earlier for futility when examining interim data, 
avoiding wasting clinical resources, and avoiding giving patients ineffective treatments.[14] One 
of the main methods for futility analysis is based on conditional power. It helps calculate the 
probability of obtaining a final significant result conditional on the data obtained at the interim 
analysis. If the probability is below a predefined threshold, the trial is terminated early. The 
planned binary outcome is defined as a good functional outcome (mRS 0-3 at 180 days) 
comparing MIS surgery groups of early (evacuation timing < 55 hrs) and late (evacuation timing  





4.2 Statistical Framework  
4.2.1 Conditional Power 
Jennison and Turnbull (2000) illustrate the general idea in calculating conditional power 
[15]: 
The general upper one-sided conditional power at stage k for rejecting a null hypothesis 
about a parameter θ at the end of the study, given the observed test statistics, 𝑍𝑘, is 
computed as 
𝑃𝑢𝑘(θ) = Φ (




θ =  the parameter tested by the hypothesis at the end of the study 
k =  an interim stage at which the conditional power is computed    
K =  the stage that final test is computed  
Zk = the test statistic calculated from data obtained at an interim stage so far   
Ik =  the information level at stage k 
IK = the information level at the end of the study 
𝑍1−α =  z-statistic for the test with a type I error rate of α   
Consider a test of proportions of patients having mRS 0-3 at 180 days, with the following 
hypothesis, where PMed and PSurg are the population proportions in the MIS group and the 
standard medical group.  
𝐻0: PMed = 𝑃𝑆𝑢𝑟𝑔 
𝐻𝑎: PMed < 𝑃𝑆𝑢𝑟𝑔 
Components in computing conditional power for the proportion test are in 
Chang(2008)[16]  
θ = PSurg − PMed the expected difference under the alternative hypothesis  
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𝑍𝑘 = (𝑝𝑆𝑢𝑟𝑔 − 𝑝𝑀𝑒𝑑)√𝐼?̂?   
























 the final information level  
where  
pSurg =  sample proportion for the MISTIE group at an interim stage 
pMed =  sample proportion for the standard medical group at an interim stage 
𝐼?̂?  =  estimated information from the sample at an interim stage  
𝑛Surg = MISTIE group sample size at an interim stage 
𝑛Med = Standard medical group sample size at an interim stage 
𝑁Surg = MISTIE group final sample size  
𝑁Med = Standard medical group final sample size  




Note that PMed and PSurg should be prespecified  
Generally, if 𝑃𝑢𝑘(θ) falls below 0.2 or 0.1, the study may be stopped. 
4.2.2 Bonferroni Correction  
Goeman and Solari (2014) review the general idea of Bonferroni correction for 
familywise error control on multiple testing [17]: 
Let H1, … . Hm be a family of hypotheses and 𝑝1, … . 𝑝𝑚 be their corresponding p-values. 
Let 𝑚 be the total number of null hypotheses and 𝑚0 be the number of the true null 
hypothesis. The familywise error rate (FWER) is the probability of rejecting at least one 
true 𝐻𝑖. The Bonferroni correction rejects the null hypothesis for each pi ≤
α
m
  , therefore 
controlling the FWER at ≤ α.  
15 
 


















We simulate the MIS early surgery group (evacuation timing < 55 hrs), MIS late surgery group 
(evacuation timing ≥ 55 hrs), and medical group with 1:1:1 randomization to the three arms with 
a total enrollment of n = 350, 500, 600, 800 and 1000. We generate data for standard medical-
arm participants by resampling with replacement from the original control group of MISTIE 
data. The “no enriched” MIS arm participants are generated by resampling with replacement 
from the original surgery group of MISTIE data. Data for “enriched” MIS-arm participants are 
simulated in three steps: (1) Dividing MISTIE data by patients’ median evacuation timing into 
two stratums, (2) In each stratum, dividing data by patients clot size less than 15 and greater than 
15 cc at the end of treatment. (3) Participants with clot size less than 15 and greater than 15 cc 
are resampled with replacement from each group in the prespecified ratios = 9:1, 8.5:1.5, 8:2, 
7:3. In each case, 1000 trials are simulated. We compute conditional power to decide if any arm 
should be dropped at the interim analysis (i.e., simulating 1/2 of the total enrollment of n patients 
data) based on the expected difference under the alternative hypothesis at the end of the study. 
The expected difference is determined by the original MIS date and power we expect to see at 
the endpoint. We assume true treatment effects are the same in MIS early vs. Medical, MIS late 
vs. Medical. When both surgery arms are dropped, the entire study will halt, and we don’t 
proceed to power calculation at the end of the study. We tabulate results for the following 
scenarios: (1) testing the endpoints and calculating power using binary outcome with one-sided 
level and Bonferroni Correction since multiple endpoints, (2) different scale in expected 
difference for the percentage of patients having mRS 0-3 at 180 days between 
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MISTIE(late/early) arm and standard medical arm, (3) conditional power with 0.1 and 0.2 
cutoffs. All simulations are implemented in R studio. 
4.4 Results 
 4.4.1 Baseline  
Table 4.4.1.1 shows the percentages of patients having mRS 0-3 at 180 days from the original  







Table 4.4.1.1 Proportion of patients having mRS 0-3 at 180 days from the original MISTIE II/III patient 
data. “Med” denotes patients who received standard medical care; “Surg_Early” denotes patients who 
received MIS with evacuation timing less than 55 hours; “Surg_Late” denotes patients who received MIS 
with evacuation timing larger  than 55 hours 
 
4.4.2 Expected Difference, Power and Futility Cutoff 
N 
𝛂 









350 0.025 80% 0.365 0.1045 0.1/0.2 
500 0.025 80% 0.365 0.087 0.1/0.2 
600 0.025 80% 0.365 0.0795 0.1/0.2 
800 0.025 80% 0.365 0.069 0.1/0.2 
1000 0.025 80% 0.365 0.062 0.1/0.2 
350 0.025 90% 0.365 0.121 0.1/0.2 
500 0.025 90% 0.365 0.101 0.1/0.2 
600 0.025 90% 0.365 0.092 0.1/0.2 
800 0.025 90% 0.365 0.0795 0.1/0.2 







36.5% 35.5% 43.2% 
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Table 4.4.2.1 Proposed different scenarios that are estimated at the interim analysis. 𝑃Med is the 
prespecified value for the population proportion of patient achieving mRS 0-3 at 180 days for standard 
medical arm based on the trial data; θ denotes the expected minimally detectable difference of population 
proportion between the surgery arm (𝑃Surg) and the standard medical arm (𝑃Med) under different desired 
power; and “Stopping cutoff” denotes thereshold for dropping arm at the interim analysis.  
 
Table 4.4.2.1 shows the expected difference (θ) of population proportion of patients 
having mRS 0-3 at 180 days between the MIS (late/early) arm and the standard medical 
arm under different cases of desired power, the sample size of each arm, and type I error 
rate. We use θ from the table to calculate the conditional power in the simulated studies 
and determine whether the MIS arm(s) should be dropped or not given prespecified 
futility criteria.  
4.4.3 Results  















H0 rejected: late arm v med.           early arm v med           early arm v med late arm v med  both v med 
 
 






N = 600, no enhancement 































Figure 4.4.3.1 Futility drop results and the number of simulated trials detecting treatment effects. The 
sample size of each arm is n=600, interim stopping criteria is 0.2 and the enhancement is prespecified 
 
Figure 4.4.3.1 shows the results when the sample size of each arm is 600. The second row 
of each flow chart shows the futility drop results between simulated MIS arm having no 
enhancement and arm having 90% patients down to 15cc or less clot at the end of 
treatment. The stopping cutoff at interim analysis is specified to 0.2, and the desired level 
of true treatment effect is 0.0795 comparing MIS (early/late) arm vs. Medical arm. The 
third row of each flow chart represents the number of trials detecting the difference 
between the surgery arm and standard medical arm under different futility scenarios 
(early/late/both surgery arms dropped at the interim analysis).  Detailed futility results 
with different cases of power, enhancement fraction, stopping cutoff are displayed in 
Appendix 2.  
N = 600, 90% enhancement 














Figure 4.4.3.2 Number of times that early/late surgery group drop at the interim analysis under different 
settings. The settings include different cutoff point, expected power and the sample size of arm; x-axis 
denotes sample size of each arm, y-axis denotes the number of dropping times, the title shows the stopping 
cut point and expected power; “enrich” shows what percentage of patients down to 15cc or less clot is 
included in the simulated trial; “cut” means arm stopping criteria in the interim analysis  
 
Figure 4.4.3.2 shows the results of 1000 simulated trials under different scenarios and 
compares the number of dropping times at interim analysis. The first and second rows of 
figures show the number of times that only dropping early/late surgery group at interim 
analysis. The third row of the figures shows the number of times that both early and late 
groups stop at interim analysis. The last row of the figures shows how many times that no 
surgery arms stop early. Line color shows the number of dropping times when having 
different enhancements for patients with 15cc or less clot at the end of treatment in the 




Figure 4.4.3.3 Proportion of simulated trials rejecting corresponding H0; x-axis denotes sample size of 
each arm; y-axis denotes the proportion of trials rejecting the corresponding H0 of the early MIS arm(first 
row), the late MIS arm(second row) or at least one MIS arm(third row); futility index 0.1,0.2 denotes the 
arm stopping criteria at the interim analysis; The red lashed horizontal line denotes desired power; Given 
the fixed desired power, prespecified enhancement ratio and sample size, powers are pretty closed so that 
we only can see solid lines in these plots.   
 
Figure 4.4.3.3 compares proportions of simulated trials detecting treatment effect in 
surgery arms based on different futility index. This figure examines results when we 
expect to have 80%, 90% power in detecting a clinically important difference between 
the surgery arm and standard medical arm at the endpoint. Given the fixed desired power 
and sample size, powers are pretty closed so that we only can see solid lines in these 
plots. The first and second rows of figures indicate the power of MIS early arm vs. 
standard medical arm and MIS late arm vs. standard medical arm. The third row of 
figures shows the power to reject at least one of the surgery arms. In addition, different 
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colors represent situations with different percentages of patients having 15cc or less clot 
at the end of treatment in the simulated trials, while “No” means there is no prespecified 
percentage.  
 
Figure 4.4.3.4 Comparison of power in rejecting at least one MIS arm between cases with and without 
futility; x-axis denotes sample size of each arm; y-axis denotes the proportion of trials rejecting at least one 
corresponding H0 of MIS arm; futility index 0.1,0.2 denotes the arm stopping criteria at the interim 
analysis; “No futility” denotes case without considering futility analysis. The red lashed horizontal line 
denotes the desired power 
 
Figure 4.4.3.4 compares the proportion of simulated trials detecting at least one MIS 
surgery arm with a significant result between simulation with and without futility 
analysis. The calculated power of no futility case can be found in Appendix 3. The first 
row of the figures shows the comparison when desired power is 0.8 in the setting with 
futility analysis, while the second row of the figures displays the situation when desired 
power is 0.9. In addition, different colors represent cases with different percentages of 
patients having 15cc or less clot at the end of treatment in the simulated trials, while 




In Figure 4.4.3.1, we use simulated trials with a sample size of each arm equal to 600 as an 
example. When having the same expected power and futility stopping criteria, simulation with 
90% enhancement of patients achieving 15cc or less clot size has fewer arm drops at the interim 
analysis. It detects more trials having differences between surgery arm and standard medical arm 
at the endpoint.  
In Figure 4.4.3.2, we should be aware of potential variability in the MIS arms stopping times at 
interim analysis but still can see a difference between simulated trials with and without 
enhancement. These figures show that MIS early (evacuation timing < 55hrs) arms usually have 
fewer stops at the interim analysis when the simulated trials propose enhancement in patients 
with 15cc or less clot at the end of treatment. If the expected power is 0.8 and interim stopping 
criteria is 0.2, there are less than approximately 500 MIS early arm stops in simulated 1000 trials 
with specified enhancement compared to simulated trials with no enhancement. A higher 
percentage of patients’ enhancement in achieving clot size 15cc or less at the end of treatment 
results in fewer opportunities that surgery arm stops at the interim analysis. We can also see that 
larger stopping criteria at the interim analysis bring more stops, which is reasonable for more 
trials to fall below the futility threshold. 
Figure 4.4.3.3 compares proportions of simulated trials detecting treatment effects under three 
settings. (1) MIS early vs. Medical (2) MIS late vs. Medical (3) at least one MIS arm. There is no 
big difference in results when proposing 0.1/0.2 stopping criteria at the interim analysis. In 
addition, the larger sample size of the arm brings higher possibilities of detecting treatment 
effects. In the setting with 90% patients enhancement in achieving clot size less than 15 cc, 
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simulations with the arm size larger than 600 can reach the desired power in detecting significant 
outcome for at least one MIS arm when the desired power is 0.8. 
Figure 4.4.3.4 compares the proportion of simulated trials detecting treatment effect between 
simulation with and without futility analysis. Different futility indexes do not have a significant 
impact in detecting treatment effects. When desired power is 0.9,  a few scenarios can reach the 
desired power. Simulations without futility analysis achieve higher power than simulations with 
futility analysis, which is reasonable that dropping arms in the simulations with futility analysis 
can dilute the detectable treatment effects. Also, we should be aware that the impact of the 
futility stopping rule on power should be small (e.g., at most 1-2% decrease in power). When 
simulations have arm size = 1000 and prespecify 90% of patients in MIS arm achieving clot size 
less than 15cc at the end of treatment, the difference of power in-between settings with and 
without futility analysis is smaller than 2.5%.  
As we can see, many factors affect the final outcomes. Thus it is necessary to set up an 
appropriate expected power and futility in the clinical study plan to balance clinical resources 













Discussion and Conclusion  
 
In this thesis work, we first introduce current research in MIS benefits to stroke patients and the 
necessity in providing power analysis and more rigorous MIS performance for future clinical 
studies. We compare the models’ performance in binary endpoint and ordinal endpoint based on 
MISTIE II/III. When examining power based on simulation, we find that larger sample size and 
higher enhancement in patients achieving 15cc or less clot size results in higher desired power. 
Absolute gains in power vary from 2% to 45%, with sample size ranging from 350 to 1000 
participants and enhancement = “No enhancement”, 70%, 80%, 85%, and 90%. When the 
sample size is above 600, desired power can be above 90% no matter the enhancement, which 
we consider potential resource waste.  We then evaluate trial results when taking into account 
futility and patients’ clot evacuation timing. Higher enhancement in MIS patients brings fewer 
stops at the interim analysis, especially in MIS early surgery arm. Higher enhancement achieves 
higher power at the endpoints. Also, simulation with enhancement narrows the gap between 
times of early and late surgery arm dropped.  
In summary, to balance desired power and clinical resources, we suggest that in detecting MIS 
treatment effect for ICH patients compared to standard medical care, future clinical studies 
should have as many patients as possible achieving 15cc or less clot size at the end of MIS. It is 
reasonable if the sample size of each arm ≥ 800 with power = 80%. If clinicians prefer a smaller 
25 
 
sample size, then analysis of treatment effects with covariate adjustment and ordinal endpoints 
can be considered. 
This study estimates the effect size from the actual MIS data, which could be a potential 
limitation. Furthermore, the analyses in Chapter 3 and 4 do not take into account covariate 
adjustment. We recommend considering covariate adjustment in the future analysis. Another 
limitation is that since clot volume is a post-treatment variable, there could be unmeasured 



















1. Demographic and baseline characteristics for MISTIE II/III clinical trials stratified by 
patients symptom onset to MIS surgery hours (Late ≥ 55hrs versus Early < 55hrs ). 
“Stability CT ICH” denotes Stability CT Intracerebral hemorrhage(ICH) volume, 
“Stability CT IVH” denotes Stability CT Intraventricular hemorrhage (IVH) volume, 
Glasgow Coma Scale (GCS) is a scoring system used to describe patients’ degree of 
consciousness following a brain injury. [11] The clot location is either lobar or deep 
(putamen or thalamus). 
 
“mRS”: Patients Modified Rankin Scale(mRS) - ordinal at day 180, range from 0 to 6 
where 0 is no symptom, 1 is no significant disability and able to carry out all pre-stroke 
activities, 2 is slight disability and unable to carry out all pre-stroke activities, 3 is 
moderate disability with requiring some external help, 4 is moderately severe disability 
and unable to walk or attend to bodily functions without others’ assistance, 5 is severe 
disability with requiring continuous care, 6 is death; binary at day 180, 1 = good mRS (0-







1. Futility results (out of 1000 simulated trials) when expected power is 80% with 
different arm sizes n = 350, 500, 600, 800, and 1000. Stopping cutoff = 0.2 at interim 
analysis, with no enhancement or having enhancement = 90%, 85%, 80%, 70% of 




MIS early arm 
Only drop 
MIS late arm 
Drop both 
MIS arms  
Enhancement 
350 463 17 92 No 
500 496 2 58 No 
600 561 2 41 No 
800 582 2 31 No 
1000 567 1 12 No 
350 33 45 18 90% 
500 25 24 6 90% 
600 17 20 3 90% 
800 6 7 1 90% 
1000 2 2 0 90% 
350 63 61 25 85% 
500 38 32 12 85% 
600 30 37 10 85% 
800 21 17 6 85% 
1000 8 5 0 85% 
350 93 84 43 80% 
500 62 71 29 80% 
600 53 50 21 80% 
800 37 40 10 80% 
1000 23 16 10 80% 
350 123 142 118 70% 
500 124 125 133 70% 
600 138 113 96 70% 
800 114 101 74 70% 





2. The number of simulated trials that detect a significant difference between surgery 
arm and standard medical arm given the different stopping scenarios. The expected 
power  is 80%, arm sizes n = 350, 500, 600, 800, and 1000, stopping cutoff = 0.2 at 
the interim analysis, with no enhancement or having enhancement = 90%, 85%, 80%, 

































The table’s heading denotes different situations at the interim analysis, “NA” denotes that the surgery 
arm was not dropped in any of the 1000 simulations for this scenario. For example, 118/463 means 188 
























Both  Total 
350 118/463 0/17 2 195 8 205/428 No 
500 196/496 0/2 1 268 4 273/444 No 
600 278/561 0/2 1 259 3 263/396 No 
800 356/582 0/2 0 309 3 312/385 No 
1000 421/567 0/1 0 363 7 370/420 No 
350 7/33 11/45 147 151 311 609/904 90% 
500 13/25 7/24 151 150 487 788/945 90% 
600 7/17 7/20 123 95 628 846/960 90% 
800 3/6 4/7 76 74 785 935/986 90% 
1000 1/2 2/2 39 53 882 974/996 90% 
350 9/63 13/61 145 119 199 463/851 85% 
500 9/38 8/32 154 160 303 617/918 85% 
600 7/30 12/37 141 157 403 701/923 85% 
800 9/21 7/17 130 125 552 807/956 85% 
1000 4/8 0/5 110 93 704 907/987 85% 
350 5/93 12/84 112 109 112 333/780 80% 
500 11/62 16/71 146 140 187 473/838 80% 
600 8/53 8/50 159 147 233 539/876 80% 
800 10/37 10/40 154 153 353 660/913 80% 
1000 9/23 6/16 137 152 452 741/951 80% 
350 6/123 5/142 48 42 28 118/617 70% 
500 6/124 8/125 61 58 37 156/618 70% 
600 4/138 8/113 53 74 43 170/653 70% 
800 5/114 8/101 76 78 63 217/711 70% 





3. Futility results (out of 1000 simulated trials) when expected power is 80% with 
different arm sizes n = 350, 500, 600, 800, and 1000. Stopping cutoff = 0.1 at interim 
analysis, with no enhancement or having enhancement = 90%, 85%, 80%, 70% of 




MIS early arm 
Only Drop 




350 343 16 34 No 
500 361 2 26 No 
600 421 0 21 No 
800 435 0 10 No 
1000 417 0 2 No 
350 14 18 7 90% 
500 3 9 0 90% 
600 6 6 0 90% 
800 2 1 1 90% 
1000 0 0 0 90% 
350 28 24 8 85% 
500 20 11 1 85% 
600 18 15 5 85% 
800 8 6 0 85% 
1000 2 1 0 85% 
350 43 43 18 80% 
500 29 42 4 80% 
600 21 29 11 80% 
800 8 15 4 80% 
1000 8 7 1 80% 
350 79 91 41 70% 
500 80 84 51 70% 
600 86 74 37 70% 
800 70 54 29 70% 







4. The number of simulated trials that detect a significant difference between surgery 
arm and standard medical arm given the different stopping scenarios. The expected 
power is 80%, arm sizes n = 350, 500, 600, 800, and 1000, stopping cutoff = 0.1 at 
the interim analysis, with no enhancement or having enhancement = 90%, 85%, 80%, 


































The table’s heading denotes different situations at the interim analysis, “NA” denotes that the surgery 
arm was not dropped in any of the 1000 simulations for this scenario. For example, 70/343 means 70 
























Both  Total 
350 70/343 0/16 3 243 8 254/607 No 
500 123/361 0/2 1 344 4 349/611 No 
600 189/421 NA 1 348 3 352/558 No 
800 240/435 NA 1 426 4 431/555 No 
1000 290/417 NA 0 496 7 503/581 No 
350 4/14 5/18 154 155 311 620/961 90% 
500 1/3 2/9 156 160 490 806/988 90% 
600 0/6 1/6 128 101 630 859/988 90% 
800 0/2 0/1 80 77 785 942/996 90% 
1000 NA NA 41 54 882 977/1000 90% 
350 2/28 3/24 154 127 200 481/940 85% 
500 4/20 3/11 161 166 303 630/968 85% 
600 5/18 3/15 149 162 404 715/962 85% 
800 0/8 1/6 135 134 553 822/986 85% 
1000 0/2 0/1 110 97 705 912/997 85% 
350 2/43 1/43 122 111 114 347/896 80% 
500 4/29 7/42 155 147 187 489/925 80% 
600 1/21 6/29 162 154 233 549/939 80% 
800 1/8 3/15 162 163 353 678/973 80% 
1000 4/8 1/7 142 156 453 751/984 80% 
350 1/79 1/91 52 47 28 127/789 70% 
500 2/80 4/84 64 62 38 164/785 70% 
600 1/86 3/74 57 78 44 179/803 70% 
800 3/70 3/54 81 81 63 225/847 70% 





5. Futility results (out of 1000 simulated trials) when expected power is 90% with 
different arm sizes n = 350, 500, 600, 800, and 1000. Stopping cutoff = 0.2 at interim 
analysis, with no enhancement or having enhancement = 90%, 85%, 80%, 70% of 




MIS early arm 
Only Drop 
MIS late arm 
Drop both 
MIS early arm 
Enhancement 
350 373 16 49 No 
500 432 2 31 No 
600 454 1 24 No 
800 486 1 14 No 
1000 476 1 5 No 
350 16 21 8 90% 
500 6 13 0 90% 
600 7 9 0 90% 
800 2 3 1 90% 
1000 2 1 0 90% 
350 35 29 12 85% 
500 22 17 5 85% 
600 22 18 5 85% 
800 12 9 1 85% 
1000 3 2 0 85% 
350 51 49 25 80% 
500 40 53 14 80% 
600 23 34 15 80% 
800 13 23 5 80% 
1000 12 11 3 80% 
350 88 104 56 70% 
500 91 110 70 70% 
600 98 78 45 70% 
800 80 71 39 70% 








6. The number of simulated trials that detect a significant difference between surgery 
arm and standard medical arm given the different stopping scenarios. The expected 
power is 90%, arm sizes n = 350, 500, 600, 800, and 1000, stopping cutoff = 0.2 at 
the interim analysis, with no enhancement or having enhancement = 90%, 85%, 80%, 


































The table’s heading denotes different situations at the interim analysis, “NA” denotes that the 
surgery arm was not dropped in any of the 1000 simulations for this scenario. For example, 
85/373 means 85 trials detect a significant difference in the endpoint given 373 trials having 























Both  Total 
350 85/373 0/16 3 228 8 239/562 No 
500 158/432 0/2 1 309 4 314/535 No 
600 210/454 0/1 1 327 3 331/521 No 
800 272/486 0/1 1 393 4 398/499 No 
1000 340/476 0/1 0 446 7 453/518 No 
350 4/16 5/21 154 155 311 620/955 90% 
500 2/6 5/13 154 159 489 802/981 90% 
600 0/7 3/9 126 101 630 857/984 90% 
800 0/2 2/3 78 77 785 940/994 90% 
1000 1/2 1/1 40 53 882 975/997 90% 
350 3/35 3/29 154 125 200 479/924 85% 
500 3/22 4/17 158 166 303 627/956 85% 
600 6/22 3/18 149 160 404 713/955 85% 
800 3/12 2/9 134 131 553 818/978 85% 
1000 1/3 0/2 110 97 704 911/995 85% 
350 3/51 3/49 120 110 114 344/875 80% 
500 6/40 10/53 152 145 187 484/893 80% 
600 1/23 6/34 161 154 233 548/928 80% 
800 3/13 4/23 161 161 353 675/959 80% 
1000 4/12 4/11 139 156 453 748/974 80% 
350 2/88 2/104 51 46 28 125/752 70% 
500 5/91 6/110 63 59 37 159/729 70% 
600 3/98 4/78 56 76 44 176/779 70% 
800 3/80 3/71 81 81 63 225/810 70% 





7. Futility results (out of 1000 simulated trials) when expected power is 90% with 
different arm sizes n = 350, 500, 600, 800, and 1000. Stopping cutoff = 0.1 at interim 
analysis, with no enhancement or having enhancement = 90%, 85%, 80%, 70% of 




MIS early arm 
Only Drop 
MIS late arm 
Drop both 
MIS early arm 
Enhancement 
350 255 10 14 No 
500 273 2 16 No 
600 301 0 12 No 
800 321 1 4 No 
1000 300 0 2 No 
350 9 8 2 90% 
500 1 7 0 90% 
600 5 2 0 90% 
800 0 0 0 90% 
1000 0 0 0 90% 
350 16 15 1 85% 
500 9 4 0 85% 
600 6 9 3 85% 
800 5 2 0 85% 
1000 2 1 0 85% 
350 24 23 5 80% 
500 14 25 1 80% 
600 12 17 3 80% 
800 5 8 0 80% 
1000 3 4 0 80% 
350 53 55 13 70% 
500 65 53 25 70% 
600 56 42 16 70% 
800 41 45 12 70% 







8. The number of simulated trials that detect a significant difference between surgery 
arm and standard medical arm given the different stopping scenarios. The expected 
power is 90%, arm sizes n = 350, 500, 600, 800, and 1000, stopping cutoff = 0.1 at 
the interim analysis, with no enhancement or having enhancement = 90%, 85%, 80%, 


































The table’s heading denotes different situations at the interim analysis, “NA” denotes that the surgery 
arm was not dropped in any of the 1000 simulations for this scenario. For example, 46/255 means 46 
trials detect a significant difference in the endpoint given 255 trials having MIS early arm dropped at 






















Both  Total 
350 46/255 0/10 4 266 9 279/721 No 
500 85/273 0/2 4 382 4 390/709 No 
600 122/301 NA 3 414 4 421/687 No 
800 174/321 0/1 1 492 4 497/674 No 
1000 196/300 NA 0 590 7 597/698 No 
350 1/9 2/8 157 158 311 626/981 90% 
500 0/1 2/7 156 161 490 807/992 90% 
600 0/5 0/2 129 101 630 860/993 90% 
800 NA NA 81 77 785 943/1000 90% 
1000 NA NA 41 54 882 977/1000 90% 
350 1/16 2/15 155 128 200 483/968 85% 
500 3/9 0/4 164 167 303 634/987 85% 
600 1/6 2/9 150 167 404 721/982 85% 
800 0/5 0/2 136 134 553 823/993 85% 
1000 0/2 0/1 110 97 705 912/997 85% 
350 1/24 0/23 123 112 114 349/948 80% 
500 1/14 4/25 158 150 187 495/960 80% 
600 0/12 3/17 165 155 233 553/968 80% 
800 0/5 2/8 163 164 353 680/987 80% 
1000 1/3 0/4 143 159 453 755/993 80% 
350 1/53 0/55 53 47 28 128/879 70% 
500 1/65 1/53 67 63 38 168/857 70% 
600 1/56 1/42 59 78 44 181/886 70% 
800 1/41 2/45 82 83 63 228/902 70% 







1. The proportion of simulated trials detecting at least one MIS arm is significant under 













350 0.341 0.483 0.712 0.81 0.893 
500 0.497 0.638 0.874 0.935 0.969 
600 0.566 0.728 0.942 0.973 0.991 
800 0.702 0.85 0.982 0.996 0.999 
1000 0.804 0.927 0.992 1 1 
N denotes simulated arm size for the MIS and the standard medical groups; “Enhancement” denotes the 
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